Company: NCEL
Filing Date: 2025-09-10
Form Type: 424B3
Source: 0001213900-25-086600
Chunk: 838

Company: NewcelX Ltd.
Filing Date: 2025-09-10
Form: 424B3
Chunk 838
---
 amount of CHF 494,000 for the fixed compensation and a new maximum aggregate amount of CHF 2,206,000 for the variable compensation of the Company’s executive officers. Furthermore the board proposes to set the grant of equity or equity linked instruments at a maximum aggregate amount of CHF 991,000 for the compensation of the Company’s executive officers and the board proposes the participation in the purchase of a run-off insurance policy for the Company’s executive officers, to be effective at the time of the merger’s completion, with coverage amounts and terms to be approved by the Board of Directors, in each case for each of the financial year 2025 and the financial year 2026. 13. Approval of Contingent Value Rights (CVR) Agreement on an Advisory Basis The board proposes to approve the CVR Agreement in the sense of an advisory vote. The company intends to work towards selling its existing R&D assets under development, excluding the DOXA asset. 14. Approval of Option and RSU Conversion on an Advisory Basis The board proposes to approve the planned conversion of outstanding options and RSUs issued by Kadimastem into equivalent securities with identical rights in Company at the time of the completion of the transactions contemplated by the Merger Agreement in the sense of an advisory vote. Date Signature Signature, if held jointly To change the address on your account, please check the box at right and indicate your new address. * SPECIMEN * AC:ACCT9999 90.00 Annex H-2